文献速递临床试验与 GCP基础与转化研究

脂肪乳后处理对体外循环心脏手术患者影响的随机对照试验方案

Intralipid postconditioning in patients of cardiac surgery undergoing cardiopulmonary bypass (iCPB): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-11-23

本研究为单中心、前瞻性、双盲、大样本随机对照试验,计划纳入1000例体外循环下心脏手术成人患者,比较脂肪乳后处理(ILPC)与生理盐水对照对住院期间主要并发症复合终点及术后30天全因死亡率的影响,并评估远期结局、心功能与生活质量。

要点

  • 脂肪乳后处理组在主动脉交叉钳开放前10分钟内静脉输注20%脂肪乳2 mL/kg。
  • 主要终点为住院期间主要并发症复合终点和术后30天全因死亡率。
  • 次要终点包括6个月和1年全因死亡率、生活质量、心功能及心肌损伤指标。

核心结论

  • 该试验旨在明确脂肪乳后处理能否改善成人心脏手术患者的短期和长期临床结局及心功能。

研究设计与样本

  • iCPB试验为正在进行的单中心、前瞻性、双盲、大样本随机对照试验。
  • 计划纳入1000例接受心脏手术的成人患者,随机分配至ILPC组或对照组。

主要发现

  • 研究组前期试点RCT显示ILPC可减少瓣膜置换术后cTnT和CK-MB释放。

关键数值与推荐

  • ILPC组在主动脉交叉钳开放前10分钟内静脉输注2 mL/kg的20%脂肪乳(中长链脂肪乳注射液C6~C24)。
  • 对照组给予等体积生理盐水。
  • 主要终点为住院期间主要并发症复合终点和术后30天全因死亡率。
  • 次要终点包括术后6个月和1年全因死亡率、术后1年内QoR-15生活质量、LVEF、LVEDS、LVEDD及CK-MB、cTnT、BNP。

临床怎么用

  • 若试验证实获益,可为脂肪乳后处理用于成人心脏手术围术期心肌保护提供临床依据。

局限性

  • 目前仅为研究方案,尚未报告临床结局数据。
  • 单中心设计可能影响结果的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intralipid is a necessary fatty acid carrier that has been safely used as an energy supplier in the clinic. It has played an important role in rescuing the cardiac arrest caused by local anesthetic toxicity. In recent years, experimental studies have shown that intralipid postconditioning (ILPC) could reduce myocardial ischemic/reperfusion (I/R) injuries. Our research group has innovatively conducted a pilot randomized controlled trial (RCT), and the results showed that ILPC could reduce the release of cTnT and CK-MB, biomarkers of myocardial I/R injury, in valve replacement surgery. However, the potential effects of ILPC on the clinical outcome of adult cardiac surgery patients are unclear. Intralipid postconditioning in patients of cardiac surgery undergoing cardiopulmonary bypass (iCPB) trial is aimed to further study whether ILPC could improve short-term and long-term clinical outcome, as well as cardiac function in adult cardiac surgery patients. METHODS: The iCPB trial is an ongoing, single-center, prospective, double-blinded, large sample RCT. In total, 1000 adults undergoing cardiac surgery will be randomly allocated to either the ILPC group or the control group. The intervention group received an intravenous infusion of 2 mL/kg of 20% intralipid (medium-chain and long-chain fat emulsion injection C6~C24, Pharmaceutical) within 10 min before aortic cross-unclamping, and the control group received an equivalent volume of normal saline. The primary endpoints are complex morbidity of major complications during hospitalization and all-cause mortality within 30 days after surgery. The secondary endpoints include (1) all-cause mortality 6 months and 1 year postoperatively; (2) the quality of life within 1 year after surgery, using the QoR-15 questionnaire; (3) the postoperative cardiac function evaluated by LVEF, LVEDS, and LVEDD, and the myocardial injury evaluated by CK-MB, cTnT, and BNP; and (4) short-term clinical outcomes during hospitalization and total cost are also detailed evaluated. DISCUSSION: The iCPB trial is the first to explore ILPC on the clinical outcome of adult cardiac surgery patients. The results are expected to provide potential evidences about whether ILPC could reduce the morbidity and mortality and improve the cardiac function and quality of life. Therefore, the results will provide a rationale for the evaluation of the potentially clinically relevant benefit of intralipid therapy. TRIAL REGISTRATION: Chictr.org.cn ChiCTR1900024387. Prospectively registered on 9 July 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yuan Y, Xiong H, Zhang Y, et al. Intralipid postconditioning in patients of cardiac surgery undergoing cardiopulmonary bypass (iCPB): study protocol for a randomized controlled trial. Trials. 2020. PMID: 33228739. doi:10.1186/s13063-020-04854-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。